Location of Repository

Increased Fas and Bcl-2 Expression on Peripheral Blood T and B Lymphocytes from Juvenile-Onset Systemic Lupus Erythematosus, but not from Juvenile Rheumatoid Arthritis and Juvenile Dermatomyositis

By Bernadete L. Liphaus, Maria H. B. Kiss, Solange Carrasco and Claudia Goldenstein-Schainberg

Abstract

Defective regulation of apoptosis may play a role in the development of autoimmune diseases. Fas and Bcl-2 proteins are involved in the control of apoptosis. The aims of this study were to determine the expression of Fas antigen and Bcl-2 protein on peripheral blood T and B lymphocytes from patients with juvenile-onset systemic lupus erythematosus (JSLE), juvenile rheumatoid arthritis (JRA) and juvenile dermatomyositis (JDM). Thirty-eight patients with JSLE, 19 patients with JRA, 10 patients with JDM and 25 healthy controls entered the study. Freshly isolated peripheral blood mononuclear cells (PBMC) were stained for lymphocyte markers CD3, CD4, CD8, CD19 and for Fas and Bcl-2 molecules. Expressions were measured by three-color flow cytometry. Statistical analysis was performed using Kruskal–Wallis test. Percentages of freshly isolated T lymphocytes positively stained for Fas protein from JSLE patients were significantly increased compared to healthy controls, patients with JRA and patients with JDM. Percentages of B lymphocytes positive for Fas from JSLE patients were higher than healthy controls and JRA patients. In addition, Fas expression on T cells from patients with JRA was increased compared to JDM patients. Otherwise, Fas expression on T and B cells from JRA and JDM patients were similar to healthy controls. MFI of Bcl-2 positive T lymphocytes from JSLE patients were significantly increased compared to healthy controls and JRA patients. MFI of Bcl-2 protein on B lymphocytes from JSLE patients was similar to healthy controls and patients with JRA and JDM. Bcl-2 expression did not differ between JRA and JDM patients and healthy controls. In conclusion, increased expression of Fas and Bcl-2 proteins observed in circulating T and B lymphocytes from patients with JSLE, but not from patients with JRA and JDM, suggests that abnormalities of apoptosis may be related to the pathogenesis of JSLE and probably are not a result of chronic inflammation

Topics: Research Article
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:2270762
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (1994). Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus.
    2. (2001). Advances in immunology: Tolerance and autoimmunity.
    3. (1998). Analysis of the NF-kappa B p65 subunit, Fas antigen, Fas ligand and Bcl-2 related proteins in the synovium of RA and polyarticular JRA.
    4. (2000). Apoptosis in systemic lupus erythematosus. Clinical implications.
    5. (2003). Apoptosis of peripheral blood lymphocytes in patients with juvenile idiopathic arthritis. Ann Rheum Dis 62(8):761–763.
    6. (1997). Apoptosis: An overview.
    7. (1994). Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes.
    8. (1994). Bcl-2 and Fas, molecules which influence apoptosis. A possible role in systemic lupus erythematosus?
    9. (1995). Bcl-2 expression is unaltered in unfractionated peripheral blood mononuclear cells in patients with systemic lupus erythematosus.
    10. (1993). Bcl-2 functions in an antioxidant pathway to prevent apoptosis.
    11. (2000). Bcl-2, p53 and c-myc expression in juvenile dermatomyositis.
    12. (1977). Current proposed revision of JRA criteria.
    13. (1997). Cytotoxic mechanisms in inflammatory myopaties. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells.
    14. (1991). Enforced Bcl-2 expression in B lymphoid cells prolongs antibody responses and elicits autoimmune disease.
    15. (1994). Expression and function of Fas antigen and Bcl-2 in human systemic lupus erythematosus lymphocytes.
    16. (1999). Fas and Fas ligand interaction induces apoptosis in inflammatory myopathies: CD4 þ T cellscause musclecell injury directly in polymyositis.
    17. (2001). Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): Relation to lymphocyte activation and disease activity.
    18. (1996). Fas gene mutations in the Canele-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity.
    19. (1994). High levels of Bcl-2 protein in circulating T lymphocytes, but not B lymphocytes of patients with systemic lupus erythematosus. Arthritis Rheum 10:1423–1430.
    20. (1997). Increased rate of apoptosis and decreased expression of Bcl-2 protein in peripheral blood lymphocytes from patients with active systemic lupus erythematosus.
    21. (2001). Introduction to flow cytometry.
    22. (1999). Lymphocyte apoptosis in systemic lupus erythematosus: Relationshipswith Fas expression, serum soluble Fas and disease activity. Lupus 8:508–513.
    23. (1999). Matucci Cerinic C.
    24. (1995). Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity.
    25. (1975). Polymiositis and dermatomyositis (parts 1 and 2).
    26. (2003). Programmed cell death in rheumatoid arthritis peripheral blood T-cell subpopulations determined by laser scanning cytometry.
    27. (2004). Regulation of cell death in the lymphoid system by Bcl-2 family proteins. Acta Haematol 111:42–55.
    28. SchollerJ,TatalN,WinchesterR.1982.The1982revisedcriteria for the classification of SLE.
    29. (1998). Synergistic effect between IL-10 and Bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus.
    30. (1995). Up-regulated expression of Fas antigen (CD95) by peripheral naı ¨ve and memory T cell subsets in patients with systemic lupus erythematosus (SLE): A possible mechanism for lymphopenia.
    31. (1997). Updating the American College of Rheumatology resived criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.